CORONA REMEDIES LIMITED CORONA NSEPHARMA
Healthcare · Drug Manufacturers - General · India
CORONA Remedies Limited, a pharmaceutical formulation company, develops, manufactures, and markets pharmaceutical products. It provides products in women's healthcare, cardio-diabeto, pain management, urology, thyroid management, respiratory, nutraceuticals, gastroenterology, and other therapeutic areas. The company was incorporated in 2004 and is based in Ahmedabad, India.
READ MORE ›₹1,676.70
+16.57% 1Y
Market & Price
Market Cap
-
Current Price
₹1,676.70
High / Low (52W)
₹1,820.20 / ₹1,347.70
Beta
-
Valuation
Stock P/E
55.25
Industry PE
37.60
Forward P/E
31.56
PEG Ratio
-
Book Value
₹122.09
Price to Book
13.73
P/S
-
EV/EBITDA
35.37
Dividend Yield
0.60%
Profitability & Returns
ROCE
29.31%
ROE
27.36%
ROA
14.96%
Profit Margin
13.19%
Op Margin
14.65%
EPS (Latest Qtr)
₹7.41
EPS (TTM)
₹30.35
Balance Sheet & Liquidity
Debt/Equity
0.22
Quick Ratio
0.53
Current Ratio
0.96
Debt
₹164.85 Cr
Total Assets
₹1,205.14 Cr
Current Assets
₹348.31 Cr
Working Capital
₹-12.86 Cr
Ownership
Promoter Holding
88.75%
Chg in Prom Hold
-
FII / Inst Holding
7.08%
Chg in FII Hold
-
Financial Snapshot
Enterprise Value
₹10,377.79 Cr
Total Revenue (TTM)
₹1,403.18 Cr
EBITDA
₹293.44 Cr
Free Cash Flow
₹74.57 Cr
Operating Cash Flow
₹229.48 Cr
Shares Outstanding
-
Gross Margin
81.40%
Payout Ratio
0.00%
Growth (CAGR)
Revenue 5Y
16.67%
Profit 5Y
29.66%
Revenue (YoY)
20.20%
Earnings (YoY)
43.60%
PROS
- Strong return on equity of 27.4%.
- Healthy ROCE of 29.3%.
- Compounding revenue at 16.7% over 5 years.
- Profit CAGR of 29.7% over 5 years.
- Generates positive free cash flow.
CONS
- Trading at a high P/E of 55.2.
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP ₹ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CORONA CORONA REMEDIES LIMITED NSEPHARMA | 1,676.70 | 55.25 | - | 0.60% | 29.31% | 27.36% | 16.67% | 29.66% |
| 2 | SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA | 1,799.20 | 37.59 | ₹4.32 L Cr | 0.92% | 17.94% | 14.72% | 10.39% | 10.65% |
| 3 | DIVISLAB Divi's Laboratories Limited NSEPHARMA | 6,667.00 | 68.97 | ₹1.77 L Cr | 0.45% | 18.96% | 16.19% | 11.27% | 12.08% |
| 4 | TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA | 4,410.80 | 68.96 | ₹1.49 L Cr | 0.86% | 9.06% | 16.98% | 13.27% | 20.21% |
| 5 | CIPLA Cipla Limited NIFTY50NSEAIPHARMA | 1,401.00 | 29.16 | ₹1.13 L Cr | 0.93% | 14.88% | 11.74% | 7.23% | 11.45% |
| 6 | DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA | 1,303.50 | 25.90 | ₹1.09 L Cr | 0.61% | 14.00% | 11.83% | 10.96% | -2.35% |
| 7 | ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA | 1,077.70 | 21.51 | ₹1.08 L Cr | 0.09% | 19.24% | 18.32% | 16.55% | 36.99% |
| 8 | LUPIN Lupin Limited NIFTY_MIDNSEPHARMA | 2,267.70 | 19.49 | ₹1.04 L Cr | 0.53% | 28.42% | 26.91% | 19.10% | 131.46% |
| 9 | MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA | 2,375.60 | 51.29 | ₹98,090.71 Cr | 0.08% | 13.78% | 12.45% | 17.73% | 14.28% |
Ad space
Quarterly Results
Figures in INR.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 297.69 Cr | 293.69 Cr | 346.29 Cr | 342.42 Cr | 353.09 Cr |
| Cost of Revenue | 55.20 Cr | 56.86 Cr | 65.78 Cr | 60.27 Cr | 66.24 Cr |
| Gross Profit | 242.49 Cr | 236.83 Cr | 280.50 Cr | 282.15 Cr | 286.85 Cr |
| Operating Expenses | 182.76 Cr | 192.65 Cr | 219.45 Cr | 208.44 Cr | 235.12 Cr |
| Operating Income | 59.73 Cr | 44.18 Cr | 61.05 Cr | 73.71 Cr | 51.73 Cr |
| EBITDA | 70.36 Cr | 55.85 Cr | 71.00 Cr | 66.32 Cr | 66.41 Cr |
| Interest Expense | 2.39 Cr | 2.20 Cr | 1.39 Cr | 1.66 Cr | 1.38 Cr |
| Pretax Income | 58.28 Cr | 43.61 Cr | 60.69 Cr | 55.21 Cr | 54.74 Cr |
| Tax Provision | 13.33 Cr | 12.06 Cr | 14.50 Cr | 13.94 Cr | 9.41 Cr |
| Net Income | 44.95 Cr | 31.55 Cr | 46.20 Cr | 41.27 Cr | 45.33 Cr |
| Diluted EPS | 7.35 | 5.16 | 7.55 | 6.75 | 7.41 |
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Revenue | 883.53 Cr | 1,013.68 Cr | 1,196.42 Cr | 1,403.18 Cr |
| Cost of Revenue | 210.95 Cr | 226.83 Cr | 236.52 Cr | 260.94 Cr |
| Gross Profit | 672.57 Cr | 786.85 Cr | 959.90 Cr | 1,142.24 Cr |
| Operating Expenses | 564.49 Cr | 659.02 Cr | 757.08 Cr | 886.67 Cr |
| Operating Income | 108.09 Cr | 127.83 Cr | 202.82 Cr | 255.57 Cr |
| EBITDA | 133.38 Cr | 158.25 Cr | 246.29 Cr | 285.26 Cr |
| Interest Expense | 2.38 Cr | 11.49 Cr | 10.60 Cr | 6.97 Cr |
| Pretax Income | 110.89 Cr | 118.48 Cr | 198.53 Cr | 240.42 Cr |
| Tax Provision | 25.96 Cr | 27.98 Cr | 49.10 Cr | 55.30 Cr |
| Net Income | 84.93 Cr | 90.50 Cr | 149.43 Cr | 185.12 Cr |
| Diluted EPS | 13.89 | 14.80 | 24.43 | 30.27 |
Compounded Sales Growth
| 5 Years: | 16.67% |
| 1 Year: | 20.20% |
Compounded Profit Growth
| 5 Years: | 29.66% |
| 1 Year: | 43.60% |
Stock Price Performance
| 1 Year: | +16.57% |
| 6 Months: | - |
| 3 Months: | +10.01% |
| 1 Month: | -0.50% |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Total Assets | 595.02 Cr | 830.58 Cr | 929.86 Cr | 1,205.14 Cr |
| Current Assets | 291.49 Cr | 289.92 Cr | 338.87 Cr | 348.31 Cr |
| Cash & Equivalents | 14.49 Cr | 3.16 Cr | 3.22 Cr | 1.83 Cr |
| Inventory | 105.40 Cr | 98.34 Cr | 129.48 Cr | 125.00 Cr |
| Receivables | 86.99 Cr | 99.93 Cr | 118.29 Cr | 145.55 Cr |
| Total Liabilities | 186.50 Cr | 350.17 Cr | 323.52 Cr | 458.28 Cr |
| Current Liabilities | 137.37 Cr | 224.19 Cr | 239.59 Cr | 361.17 Cr |
| Long Term Debt | 0 | 67.00 Cr | 16.00 Cr | 0 |
| Total Debt | 27.96 Cr | 158.96 Cr | 86.23 Cr | 164.85 Cr |
| Total Equity | 408.52 Cr | 480.41 Cr | 606.34 Cr | 746.86 Cr |
| Shares Outstanding | 6.12 Cr | 6.12 Cr | 6.12 Cr | 6.12 Cr |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Operating Cash Flow | 102.70 Cr | 156.76 Cr | 190.49 Cr | 229.48 Cr |
| Investing Cash Flow | -50.24 Cr | -266.64 Cr | -83.86 Cr | -256.15 Cr |
| Financing Cash Flow | -44.75 Cr | 98.55 Cr | -106.57 Cr | 25.28 Cr |
| Capital Expenditure | -94.76 Cr | -286.34 Cr | -91.66 Cr | -174.14 Cr |
| Free Cash Flow | 7.94 Cr | -129.58 Cr | 98.83 Cr | 55.34 Cr |
| Net Change in Cash | 7.71 Cr | -11.34 Cr | 6.00 L | -1.39 Cr |
Ratios (Annual)
Figures in %.
| Metric | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Gross Margin % | 76.1% | 77.6% | 80.2% | 81.4% |
| Operating Margin % | 12.2% | 12.6% | 17.0% | 18.2% |
| Net Margin % | 9.6% | 8.9% | 12.5% | 13.2% |
| ROE % | 20.8% | 18.8% | 24.6% | 24.8% |
| ROCE % | 23.6% | 21.1% | 29.4% | 30.3% |
Shareholding Pattern
Insiders
88.75%
Institutions
7.08%
Public Float
63.01%
Analyst View
Loading analyst coverage…
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CORONA
No recent headlines available.